Volume 35, Issue 3 (6-2024)
Studies in Medical Sciences 2024, 35(3): 238-249 |
Back to browse issues page
Ethics code: IR.MUQ.REC.1400.115
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shajari R, Mohammadbeigi A, Ahmadpour S, Shakeri M, Adeli S H, Vafaeimanesh J, et al . EVALUATION OF THE EFFICACY OF RECIGEN AND REMDESIVIR DRUGS IN THE TREATMENT OF COVID-19 OUTPATIENTS: A COMPARATIVE STUDY IN QOM CITY, IRAN. Studies in Medical Sciences 2024; 35 (3) :238-249
URL: http://umj.umsu.ac.ir/article-1-6214-en.html
URL: http://umj.umsu.ac.ir/article-1-6214-en.html
Rasuol Shajari 
, Abolfazl Mohammadbeigi , Sajjad Ahmadpour , Mansoureh Shakeri , Seyed Hasan Adeli , Jamshid Vafaeimanesh , Reihane Tabaraii , Seyed Sajad Hosseini , Akram Asghari *
, Abolfazl Mohammadbeigi , Sajjad Ahmadpour , Mansoureh Shakeri , Seyed Hasan Adeli , Jamshid Vafaeimanesh , Reihane Tabaraii , Seyed Sajad Hosseini , Akram Asghari *
Assistant Professor of Pulmonary Diseases, Clinical Research of Development Unit, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom Iran (Corresponding Author) , akramasghari11@yahoo.com
Abstract: (1236 Views)
Background & Aim: The COVID-19 pandemic has highlighted the need for effective treatment options for outpatients. Resigen and Remdesivir are two commonly used drugs, but their relative effectiveness in treating outpatients with COVID-19 is unclear. The purpose of this study is to compare the effectiveness of Resigen and Remdesivir in the treatment of outpatients with COVID-19.
Materials & Methods: The present study is a retrospective cohort study with an available sampling method by referring to the records of Mitla patients with covid 19 referred to the respiratory clinic of Shahid Beheshti Hospital (the group receiving interferon beta 1a) and reviewing the electronic files of the patients. Referrals to the specialized lung and emergency clinic of Shahid Beheshti Hospital in Qom with inpatient records (remdesivir receiving group) were conducted between April and August 2021 and the information was created, extracted and analyzed through the researcher's checklist.
Results: The mean age of the patients was 48.12±14.36 years. Only 30 patients (6%) were hospitalized and 466 patients (94%) were treated as outpatients. This study found no significant association between hospitalization and mortality.
Conclusion: Our study suggests that early treatment with resection or remdesivir may reduce the risk of hospitalization and mortality in outpatients with COVID-19. These findings have implications for the management of COVID-19 in ambulatory settings.
Materials & Methods: The present study is a retrospective cohort study with an available sampling method by referring to the records of Mitla patients with covid 19 referred to the respiratory clinic of Shahid Beheshti Hospital (the group receiving interferon beta 1a) and reviewing the electronic files of the patients. Referrals to the specialized lung and emergency clinic of Shahid Beheshti Hospital in Qom with inpatient records (remdesivir receiving group) were conducted between April and August 2021 and the information was created, extracted and analyzed through the researcher's checklist.
Results: The mean age of the patients was 48.12±14.36 years. Only 30 patients (6%) were hospitalized and 466 patients (94%) were treated as outpatients. This study found no significant association between hospitalization and mortality.
Conclusion: Our study suggests that early treatment with resection or remdesivir may reduce the risk of hospitalization and mortality in outpatients with COVID-19. These findings have implications for the management of COVID-19 in ambulatory settings.
References
1. Organization WH. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. 2020. 2020. [DOI:10.26633/RPSP.2021.56] [PMID] []
2. Pranata R, Huang I, Lim MA, Yonas E, Vania R, Kuswardhani RAT. Delirium and mortality in coronavirus disease 2019 (COVID-19)-a systematic review and meta-analysis. Arch Gerontol Geriatr 2021;95:104388. [DOI:10.1016/j.archger.2021.104388] [PMID] []
3. Pranata R, Huang I, Raharjo SB. Incidence and impact of cardiac arrhythmias in coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Indian Pacing Electrophysiology J 2020;20(5):193-8. [DOI:10.1016/j.ipej.2020.08.001] [PMID] []
4. Hollander JE, Carr BG. Virtually perfect? Telemedicine for COVID-19. N Engl J Med 2020;382(18):1679-81. [DOI:10.1056/NEJMp2003539] [PMID]
5. Lam PW, Sehgal P, Andany N, Mubareka S, Simor AE, Ozaldin O, et al. A virtual care program for outpatients diagnosed with COVID-19: a feasibility study. Can Med Assoc J 2020;8(2):E407-E13. DOI: [DOI:10.9778/cmajo.20200069] [PMID] []
6. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;382(19):1787-99. [DOI:10.1056/NEJMoa2001282] [PMID] []
7. Sadeghi A, Ali Asgari A, Norouzi A, Kheiri Z, Anushirvani A, Montazeri M, et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother 2020;75(11):3379-85. [DOI:10.1093/jac/dkaa334] [PMID] []
8. Arevalo AP, Pagotto R, Pórfido J, Daghero H, Segovia M, Yamasaki K, et al. Ivermectin reduces coronavirus infection in vivo: a mouse experimental model. bioRxiv 2020:2020.11. 02.363242. [DOI:10.1101/2020.11.02.363242]
9. Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, et al. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial. Jama 2020;324(21):2165-76. [DOI:10.1038/s41598-021-86679-0] [PMID] []
10. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30(3):269-71. [DOI:10.1038/s41422-020-0282-0] [PMID] []
11. Pizzorno A, Padey B, Julien T, Trouillet-Assant S, Traversier A, Errazuriz-Cerda E, et al. Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia. Cell Reports Medicine. 2020;1(4). [DOI:10.1016/j.xcrm.2020.100059] [PMID] []
12. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017;9(396):eaal3653. [DOI:10.1126/scitranslmed.aal3653] [PMID] []
13. Weiss A, Jellingsø M, Sommer MOA. Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: A systematic review and meta-analysis. EBioMed 2020;58. [DOI:10.1016/j.ebiom.2020.102916] [PMID] []
14. Alothaid H, Aldughaim MS, El Bakkouri K, AlMashhadi S, Al-Qahtani AA. Similarities between the effect of SARS-CoV-2 and HCV on the cellular level, and the possible role of ion channels in COVID19 progression: a review of potential targets for diagnosis and treatment. Channels 2020;14(1):403-12. [DOI:10.1080/19336950.2020.1837439] [PMID] []
15. Mashhadi HA, Jafari F, Hosseinjani H. A New Possible Indication of Direct-acting Anti-hepatitis C Drugs in the Therapeutic Management of COVID-19: A Narrative Literature Review. Pharmaceu Sci 2021;27(Covid-19):S78-85. [DOI:10.34172/PS.2021.23]
16. 16 Gupta RK. Will SARS-CoV-2 variants of concern affect the promise of vaccines? Nat Rev Immunol 2021;21(6):340-1. [DOI:10.1016/j.ebiom.2020.102916] [PMID] []
17. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LF. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020;20(6):363-74. [DOI:10.1038/s41577-020-0311-8] [PMID] []
18. Bastard P, Zhang Q, Cobat A, Jouanguy E, Zhang S-Y, Abel L, et al. Insufficient type I IFN immunity underlies life-threatening COVID-19 pneumonia. C R Biol 2021;344(1):19-25. [DOI:10.5802/crbiol.36] [PMID]
19. Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother 2020;64(9):10. [DOI:10.1128/AAC.01061-20] [PMID] []
20. Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020;395(10238):1695-704. [DOI:10.1016/S0140-6736(20)31042-4] [PMID]
21. Consortium WST. Repurposed antiviral drugs for Covid-19-interim WHO solidarity trial results. N Eng J Med 2021;384(6):497-511. [DOI:10.1056/NEJMoa2023184] [PMID] []
22. Whittington MD, Campbell JD. Alternative pricing models for remdesivir and other potential treatments for COVID-19. Inst Clin Economic Rev 2020:1-7. [URL]
23. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19-preliminary report. N Eng J Med 2020;383(19):1813-36. [DOI:10.1056/NEJMoa2007764] [PMID] []
24. Spinner CD, Gottlieb RL, Criner GJ, López JRA, Cattelan AM, Viladomiu AS, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. Jama 2020;324(11):1048-57. [DOI:10.1056/NEJMoa2007764] [PMID] []
25. Goldman JD, Lye DC, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Eng J Med 2020;383(19):1827-37. [DOI:10.1056/NEJMoa2015301] [PMID] []
26. Foroghi Ghomi SY, Mohammadbeigi A, Ahmadi A, Ahmadpour S, Shakeri M, Adeli SH, Vafaeimanesh J, Tabaraii R, Shajari R, Vahedian M, Asghari A. Evaluation of the Effectiveness of Remdesivir in the Treatment of COVID-19 Outpatients: A Retrospective Cohort Study. Curr Drug Ther 2023;18(4):350-6. [DOI:10.2174/1574885518666230228120343]
27. Fintzi J, Bonnett T, Sweeney DA, Huprikar NA, Ganesan A, Frank MG, et al. Deconstructing the Treatment Effect of Remdesivir in the Adaptive COVID-19 Treatment Trial-1: Implications for Critical Care Resource Utilization. Clin infect Dis 2021. [DOI:10.1093/cid/ciab712] [PMID] []
28. Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Eng J Med 2021;385(15):1382-92. [DOI:10.1056/NEJMoa2102685] [PMID] []
29. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. New England Journal of Medicine. 2021;385(23):e81. [DOI:10.1056/NEJMoa2108163] []
30. Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Eng J Med 2022;386(4):305-15. [DOI:10.1056/NEJMoa2116846] [PMID] []
31. Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Eng J Med 2021;385(21):1941-50. [DOI:10.1056/NEJMoa2107934] [PMID]
32. Reis G, Moreira Silva EA, Medeiros Silva DC, Thabane L, Campos VH, Ferreira TS, et al. Early treatment with pegylated interferon lambda for covid-19. New N Eng J Med 2023;388(6):518-28. [DOI:10.1056/NEJMoa2209760] [PMID] []
33. Khorramnia S, Jalili M, Salajegheh M, Mansouri M. Efficacy of bamlanivimab compared to standard care in treatment of the patients with COVID-19: A Systematic Review and Meta-Analysis. Stud Med Sci 2023;34(8):461-70. [DOI:10.61186/umj.34.8.461]
34. Zaboli Mahdiabadi M, Karami C, Saber E, Kamali M, Orandi A, Dadashi A, Aminizadeh M, Ahmadi-Mazhin S, Khorramnia S, Mehdi N. Effectiveness of molnupiravir in the treatment of patients with COVID-19: A Systematic Review and Meta-Analysis. Stud Med Sci 2023;33(12):857-67. [DOI:10.61186/umj.33.12.857]
35. Orandi A, Mohajeri M, Mansouri M, Salajegheh M, Jalili M, Esmaiil Zali M, Babaei H, Shiri Malekabad E, Khorramnia S. Clinical Effectiveness of Casirivimab and Imdevimab Compared with Standard of Care in COVID-19: A Systematic Review AND Meta-Analysis. Stud Med Sci 2024;34(11):727-41. [DOI:10.61186/umj.34.11.8]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
